Development of Hillchol®, a low-cost inactivated single strain Hikojima oral cholera vaccine.

导出原文传递

翻译打印收藏纠错

作者： Tarun,Sharma ^[1] ; Neeraj,Joshi ^[2] ; Ashwani,Kumar Mandyal ^[2] ; Stefan L,Nordqvist ^[3] ; Michael,Lebens ^[3] ; Vibhu,Kanchan ^[2] ; Madeleine,Löfstrand ^[3] ; Frida,Jeverstam ^[3] ; Mohammad,Mainul Ahasan ^[4] ; Imran,Khan ^[4] ; Mahbubul,Karim ^[4] ; Hasneen,Muktadir ^[4] ; Abdul,Muktadir ^[4] ; Davinder,Gill ^[2] ; Jan,Holmgren ^[5]

作者单位： MSD Wellcome Trust Hilleman Laboratories Pvt Ltd, 2(nd) Floor Nanotechnology Building, Jamia Hamdard University, Hamdard Nagar, New Delhi 110062, India. Electronic address: tarun.sharma@hillemanlabs.org. ^[1] MSD Wellcome Trust Hilleman Laboratories Pvt Ltd, 2(nd) Floor Nanotechnology Building, Jamia Hamdard University, Hamdard Nagar, New Delhi 110062, India. ^[2] Department of Microbiology and Immunology at Institute of Biomedicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. ^[3] Incepta Vaccine Ltd. Dewan Idris Road, Jirabo, Savar, Dhaka. Bangladesh. ^[4] Department of Microbiology and Immunology at Institute of Biomedicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. Electronic address: jan.holmgren@microbio.gu.se. ^[5]

关键词 Fermentation Hikojima Intestinal immunity Oral cholera vaccine Vibrio cholerae Vibriocidal antibodies